CoNoR: Novel Assessments in Colorectal Liver Metastases Resectability

  • Research type

    Research Study

  • Full title

    The CoNoR Study: Colorectal Liver Metastases - Novel Assessment Tools for Technical Resectability

  • IRAS ID

    266961

  • Contact name

    Andrew Renehan

  • Contact email

    andrew.renehan@manchester.ac.uk

  • Sponsor organisation

    University of Manchester

  • Clinicaltrials.gov Identifier

    NCT04270851

  • Duration of Study in the UK

    0 years, 11 months, 30 days

  • Research summary

    Relevance:

    Bowel cancer is one of the commonest cancers in the UK, and the liver is the most common site of spread. It is important that surgery is offered where possible in CLM(colorectal liver metastases - bowel cancer deposits in the liver), because this is the only chance of cure.

    Background:

    Research has shown that liver surgeons often make different decisions about which patients can be operated on, and that there is a role for better assessment tests to help standardise this decision.

    Potential Benefit:

    This could potentially increase access to life-saving surgery to treat CLM.

    Research Question:

    In the related CLiFF study, we are already using two detailed liver assessments to look at changes in the liver during chemotherapy: a detailed magnetic resonance scan assessment by Perspectum Diagnostics, and a newly-developed fully-licensed machine which can measure liver function more accurately by using a breath test (LiMAx test). In the CoNoR study, we will test if these two detailed assessments affect the decisions made by liver surgeons as to which cases of CLM can be operated on.

    Eligible Participants:

    1) Patients

    Patients who have CLM that involve a difficult decision on whether they can be treated by surgery will be invited to participate.

    2) Professional Participants

    Surgeons with experience of participating in decision-making regarding whether colorectal liver metastases can be treated by surgery.

    What will happen to the participants:

    1) Patients:

    Consenting participants will have one additional MR scan and LiMAx test. The anonymised results from these tests will be used to prepare an online case-based survey, used for an international group of liver surgeons to study whether these assessments change decision-making in CLM technical resectability.

    2) Professionals:

    Invited to participate in an online survey.

    Where is the study recruiting:

    At the Christie NHS Foundation Trust and Manchester Royal Infirmary.

    Funding is from the following sources:

    1. Perspectum Diagnostics
    2. The Royal College of Surgeons
    3. The Christie
    4. Manchester Royal Infirmary

  • REC name

    North West - Greater Manchester West Research Ethics Committee

  • REC reference

    20/NW/0434

  • Date of REC Opinion

    30 Nov 2020

  • REC opinion

    Further Information Favourable Opinion